Literature DB >> 22847158

CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis.

Hui He1, Gang Wu, Weijie Li, Yuecheng Cao, Yongfeng Liu.   

Abstract

BACKGROUND: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is highly expressed in hepatocellular carcinoma (HCC) and promotes cell proliferation, cell invasion, and aggressive tumor behavior. However, there have been few studies on the usefulness of CIP2A as an independent prognostic index of HCC. In the current study, the aim was to explore the association between CIP2A expression and prognosis in HCC.
METHODS: The expression of CIP2A and c-MYC was examined by immunohistochemistry in 136 HCC specimens. CIP2A mRNA expression in 27 HCC tissues was also analyzed using quantitative reverse-transcription polymerase chain reaction. The prognostic significance was analyzed by the Kaplan-Meier survival method and log-rank test. Cox regression was adopted for univariate and multivariate analysis of prognostic factors.
RESULTS: CIP2A protein was found to be highly expressed in human liver cancer samples (85/136, 62.5%) and correlated with poor survival (P<0.05). The liver cancer tissues examined exhibited much higher levels of CIP2A mRNA compared with their corresponding normal tissues (19/27, 70.3%). Furthermore, CIP2A mRNA levels were correlated with c-MYC mRNA levels. In addition, the highly expressed CIP2A was associated with recurrence (P=0.014) and invasion (P=0.017) of HCC. Patients with high CIP2A expression had both poorer overall survival (OS) and disease-free survival (DFS). On multivariate analysis, the CIP2A status was a significant prognostic factor for OS and DFS (P=0.017, P=0.026, respectively).
CONCLUSIONS: CIP2A overexpression may be useful as an independent prognostic biomarker for OS and DFS of HCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22847158     DOI: 10.1097/PDM.0b013e318249fd8b

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  19 in total

1.  Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma.

Authors:  Vivi Ann Flørenes; Elisabeth Emilsen; Hiep Phuc Dong; Mette Førsund; Ruth Holm; Ana Slipicevic
Journal:  Cancer Med       Date:  2015-02-07       Impact factor: 4.452

2.  Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion.

Authors:  M P Ward; J P Spiers
Journal:  Br J Pharmacol       Date:  2017-04-07       Impact factor: 8.739

3.  Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.

Authors:  Ae Lee Jeong; Sunyi Lee; Jeong Su Park; Sora Han; Chang-Young Jang; Jong-Seok Lim; Myung Sok Lee; Young Yang
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

4.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

5.  p90/CIP2A mediates breast cancer cell proliferation and apoptosis.

Authors:  Xinxin Liu; Bo Peng; Yang Li; Ningjing Lei; Wenjie Li; Jian-Ying Zhang
Journal:  Mol Biol Rep       Date:  2014-08-03       Impact factor: 2.316

6.  CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma.

Authors:  Lei Wang; Feng Gu; Ning Ma; Lei Zhang; Jian-Min Bian; Hong-Yong Cao
Journal:  Tumour Biol       Date:  2013-04-09

Review 7.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Authors:  Jaya Sangodkar; Caroline C Farrington; Kimberly McClinch; Matthew D Galsky; David B Kastrinsky; Goutham Narla
Journal:  FEBS J       Date:  2015-11-14       Impact factor: 5.542

8.  Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo.

Authors:  C Lambrecht; L Libbrecht; X Sagaert; P Pauwels; Y Hoorne; J Crowther; J V Louis; W Sents; A Sablina; V Janssens
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

9.  EPMA position paper in cancer: current overview and future perspectives.

Authors:  Godfrey Grech; Xianquan Zhan; Byong Chul Yoo; Rostyslav Bubnov; Suzanne Hagan; Romano Danesi; Giorgio Vittadini; Dominic M Desiderio
Journal:  EPMA J       Date:  2015-04-15       Impact factor: 6.543

10.  miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis.

Authors:  Gang Wu; Haiyang Liu; Hui He; Yawei Wang; Xiaojun Lu; Yanqiu Yu; Shuguan Xia; Xiangyu Meng; Yongfeng Liu
Journal:  BMC Cancer       Date:  2014-02-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.